Related Experiment Videos
Respiratory syncytial virus vaccines
1Department of International Health, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA.
Clinical Microbiology Reviews
|July 17, 1998
Summary
Developing effective respiratory syncytial virus (RSV) vaccines is crucial for preventing severe illness in infants and the elderly. Promising candidates include purified F protein subunit vaccines and live attenuated vaccines, with ongoing research to refine them.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Respiratory syncytial virus (RSV) is a primary cause of viral lower respiratory tract illness (LRI) globally, particularly impacting infants, children, the elderly, and immunocompromised individuals.
- Developing a successful RSV vaccine faces challenges including inadequate infant immune responses, distinct RSV groups (A and B), and historical vaccine-related disease enhancement.
- Preventing serious RSV-associated LRI is the primary objective of RSV vaccination strategies.
Purpose of the Study:
- To review the current landscape and challenges in developing effective respiratory syncytial virus (RSV) vaccines.
- To evaluate the potential of different vaccine platforms, including subunit and live attenuated approaches, for various at-risk populations.
- To discuss the role of advanced technologies like cDNA in refining vaccine candidates.
Main Methods:
- Review of existing literature on RSV vaccine development, clinical trials, and candidate evaluation.
- Analysis of different vaccine types, including purified F protein (PFP) subunit vaccines and live attenuated vaccines.
- Consideration of specific populations at risk and their unique vaccination needs.
Main Results:
- Purified F protein (PFP) subunit vaccines, such as PFP-2, show promise for the elderly and RSV-seropositive children with pulmonary conditions.
- Live cold-passaged (cp), temperature-sensitive (ts) RSV vaccines (cpts vaccines) are identified as potentially suitable for young infants.
- Ongoing research aims to refine live attenuated cpts vaccines using cDNA technology for improved attenuation, immunogenicity, and stability.
Conclusions:
- Multiple vaccine types may be necessary to effectively prevent RSV LRI across diverse populations.
- Advancements in vaccine technology, particularly cDNA, offer opportunities to engineer more effective and stable live attenuated RSV vaccines.
- Targeted vaccine strategies are essential for protecting vulnerable groups from severe RSV disease.